Relationship between metabolic parameters of 18F-FDG PET-CT and clinical characteristics in newly diagnosed multiple myeloma / 白血病·淋巴瘤

ABSTRACT

Objective:To investigate the relationship between metabolic parameters of 18F-FDG PET-CT and clinical characteristics in newly diagnosed patients with multiple myeloma (MM). Methods:The clinical data of 47 MM patients who underwent 18F-FDG PET-CT at initial diagnosis from June 2018 to December 2020 in the Second Affiliated Hospital of Anhui Medical University were retrospectively analyzed. The association of metabolic parameters of 18F-FDG PET-CT with the following clinical parameters including age, gender, disease classification, DS stage, international staging system (ISS) stage, hemoglobin, albumin, serum calcium, serum crearinine, lactate dehydrogenase, β 2-microglobulin, high-sensitivity C-reactive protein (hs-CRP), bone marrow plasma cell ratio, the number of lesions and extramedullary lesions. Results:Among 47 MM patients, in terms of tumor metabolic volume (MTV), patients at DS stage Ⅲ was higher than those at stage Ⅰ-Ⅱ [172.88 (42.69, 391.55) vs. 19.63 (4.24, 42.61), P < 0.001], patients with serum calcium ≥ 2.65 mmol/L was higher than those with serum calcium <2.65 mmol/L [310.71 (99.68, 549.62) vs. 58.00 (19.63, 248.34), P = 0.038], patients with hs-CRP ≥ 3.3 mg/L was higher than those hs-CRP < 3.3 mg/L [211.39 (57.79, 397.70) vs. 35.34 (7.91, 153.02), P = 0.002], and patients with the number of lesions >3 was higher than those with the number of lesions ≤ 3 [211.39 (57.79, 393.02) vs. 16.43 (5.12, 38.23), P < 0.001]. In terms of total lesion glycolysis (TLG) value, patients at DS stage Ⅲ was higher than those at stage Ⅰ-Ⅱ [460.44 (92.62, 1 113.85) vs. 46.68 (9.32, 89.89), P = 0.001], patients with bone marrow plasma cell ratio <10% was higher than those with bone marrow plasma cell ratio ≥10% [1 039.36 (615.28, 1 167.80) vs. 150.80 (45.36, 821.01), P = 0.031], patients with serum calcium ≥ 2.65 mmol/L was higher than those with serum calcium < 2.65 mmol/L [1 031.55 (251.87, 2 115.98) vs. 177.59 (45.82, 761.66), P = 0.033], patients with hs-CRP ≥ 3.3 mg/L was higher than those hs-CRP < 3.3 mg/L [487.40 (141.38, 1 107.02) vs. 63.44 (19.40, 634.31), P = 0.003], patients with lesion number >3 was higher than those with lesion number ≤3 [625.32 (150.80, 1 134.35) vs. 40.04 (10.96, 70.88), P < 0.001]. There were no statistically significant differences in the maximum standardized uptake value (SUV max) and mean standardized uptake value (SUV mean) among different clinical parameter groups (all P > 0.05). Conclusion:MTV and TLG in 18F-FDG PET-CT metabolic parameters can better reflect the characteristics of MM patients compared with SUV max and SUV mean.